# Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients

> **NCT02439723** · PHASE1 · WITHDRAWN · sponsor: **AHS Cancer Control Alberta**

## Conditions studied

- Metastatic Solid Malignancies
- Locally Advanced Solid Malignancies

## Interventions

- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT02439723
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-03
- **Primary completion:** 2017-06
- **Final completion:** 2017-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawal of supply of investigational product
- **Last updated:** 2021-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02439723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02439723, "Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02439723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*